INVA
InnovivaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
Q1 showed resilient operating momentum, ample liquidity, and active buybacks, while NUZOLVENCE still has a second-half-2026 availability window; if the launch lands and IST keeps compounding, the mixed royalty-plus-specialty model can support a higher multiple [#IR-2026-05-06].
Posture
Mixed
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-07-29.
What can break
Capital-allocation support from buybacks is helpful, but it may not fully offset weakness in core earnings drivers.
Momentum
18
Value
71
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $33.20 · Bear $16.00
Earnings
2026-07-29
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $35.50
Why
Momentum18 · Δ7d +9.1
Value71 · Δ7d -0.0
Sentiment60 · Δ7d +0.1
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
18
26% active weight
Current posture
7d trendSoftening
Δ7d
+9.1
Δ21d
-23.2
Value
71
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
60
34% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+4.0
Why this grade
Composite grade C. Momentum 17.9 / Value 70.5 / Sentiment 60.0
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$1.58B
Beta
0.44
Shares Out
73.81M
P/E (TTM)
15.5
P/S (TTM)
3.85
P/FCF (TTM)
7.58
Rev YoY
+10.2%
EPS YoY
-398.2%
Gross Margin
+71.4%
Op Margin
+43.2%
Net Debt
-$297.65M
Current Ratio
21.13
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology